We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Sen. Richard Burr’s (R-N.C.) bill to strengthen the federal response to public health crises and bioterrorism faces few obstacles in the Senate after being unanimously approved in committee July 19, a congressional staffer told WDL.
In a blow to the biotech industry, President Bush is threatening to use his first veto to stop legislation that would allow federal funding for human embryonic stem cell research.
Contract research organizations (CROs), finding themselves in an increasingly competitive market, are using smarter bait to try to lure clinical trial sponsors.
Any legislative fix to the current FDA approval process for follow-on biologics is likely at least two years away because of other legislative priorities and the need for lawmakers to get up to speed on this issue, a Senate staffer says.
Any legislative fix to the current FDA approval process for follow-on biologics is likely at least two years away because of other legislative priorities and the need for lawmakers to get up to speed on this issue, a Senate staffer says.
Northfield Laboratories agreed June 16 to purchase a building that will house its first commercial facility for producing PolyHeme, the company's human hemoglobin-based oxygen carrier.
Drug companies will likely have to fight the FDA in court to be able to market follow-on biologics, like Sandoz’ recombinant human growth hormone Omnitrope, according to one patent attorney.
AstraZeneca's proposal to buy out Cambridge Antibody Technology Group(CAT) will be reviewed for any potential antitrust violations, the UK Office of Fair Trading (OFT) said.